Showing results (461-470 of 760) with videos related to
Sort By:
Pageof 76
Blood|May 5, 2005
Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosisKenji Ishitsuka, Teru Hideshima, Makoto Hamasaki, et al.Proceedings of the National Academy of Sciences of the United States of America|January 11, 2007
WIP is a chaperone for Wiskott-Aldrich syndrome protein (WASP)Miguel A de la Fuente, Yoji Sasahara, Marco Calamito, et al.Cancer Research|July 9, 2009
Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235Douglas W McMillin, Melissa Ooi, Jake Delmore, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 11, 2013
Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myelomaJesús F San-Miguel, Paul G Richardson, Andreas Günther, et al.British Journal of Haematology|January 13, 2011
Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implicationsDouglas W McMillin, Jake Delmore, Joseph Negri, et al.Blood|July 24, 2010
Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myelomaGüllü Görgün, Elisabetta Calabrese, Ender Soydan, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2010
Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemiaIrene M Ghobrial, Fangxin Hong, Swaminathan Padmanabhan, et al.Cell Chemical Biology|October 24, 2017
Structure-Guided Development of a Potent and Selective Non-covalent Active-Site Inhibitor of USP7Ilaria Lamberto, Xiaoxi Liu, Hyuk-Soo Seo, et al.Oncogene|June 9, 2005
Novel inosine monophosphate dehydrogenase inhibitor VX-944 induces apoptosis in multiple myeloma cells primarily via caspase-independent AIF/Endo G pathwayKenji Ishitsuka, Teru Hideshima, Makoto Hamasaki, et al.Blood|April 9, 2004
The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistanceDharminder Chauhan, Guilan Li, Klaus Podar, et al.Pageof 76